| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.08. | Enzymatica AB: Enzymatica strengthens its management team with commercial and scientific expertise | 375 | GlobeNewswire (Europe) | Enzymatica Enzymatica is strengthening its management team with the addition of Nordic Marketing and Sales Director Joakim Tingström Nordin and Chief Scientist and Head of Production Iceland Bjarki... ► Artikel lesen | |
| 16.07. | Enzymatica AB: Quarterly report Q2/2026 Continued focus on international expansion and a stronger organization | 262 | GlobeNewswire (Europe) | Second quarter· Net sales reached SEK 7,1 (8.3) million.· The operating result totaled SEK -12.6 (-14.9) million.· Earnings per share, basic and diluted, were SEK -0.05 (-0.06).· Cash flow from operating... ► Artikel lesen | |
| 24.06. | Enzymatica AB: The evidence base for ColdZyme remains unchanged - PLOS ONE notice concerns the presentation of the Berlin II article, not the evidence base for ColdZyme | 197 | GlobeNewswire (Europe) | Enzymatica AB (publ) notes that the scientific journal PLOS ONE has published an Expression of Concern regarding an article on the company's placebo-controlled Berlin II study from 2023. The notice... ► Artikel lesen | |
| 09.06. | Enzymatica AB: Enzymatica appoints Marketing and Sales Director to accelerate ColdZyme's continued growth in the Nordics | 652 | GlobeNewswire (Europe) | Enzymatica has appointed Joakim Tingström Nordin as its new Nordic Marketing and Sales Director. He will assume the role in August and will be responsible for driving ColdZyme's commercial development... ► Artikel lesen | |
| 07.05. | Enzymatica AB: Bulletin from annual general meeting of Enzymatica AB (publ) on 7 May 2026 | 330 | GlobeNewswire (Europe) | The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.
Enzymatica AB (publ) held its annual... ► Artikel lesen | |
| 28.04. | Enzymatica AB: Quarterly report Q1/2026 - Enzymatica strengthens international position through STADA agreement | 1.256 | GlobeNewswire (Europe) | First quarter
Net sales amounted to SEK 11.4 million (12.3).
Operating result amounted to SEK -13.6.million (-18.0)
Earnings per share, before... ► Artikel lesen | |
| ENZYMATICA Aktie jetzt für 0€ handeln | |||||
| 14.04. | ENZYMATICA AB: Enzymatica publishes annual report for 2025 | 1 | Cision News | ||
| 31.03. | Enzymatica AB: Enzymatica and STADA sign partnership agreement for Germany and Austria | 969 | GlobeNewswire (Europe) | Regulatory press release
• The new partnership agreement covers the launch and distribution of Enzymatica's ColdZyme® technology in oral spray form in Germany and Austria
• The partnership combines... ► Artikel lesen | |
| 18.02. | Enzymatica AB: Year-end report 2025: New CEO takes the helm - initiates the next phase of Enzymatica's international expansion | 611 | PR Newswire | LUND, Sweden, Feb. 18, 2026 /PRNewswire/ --
Fourth quarterJanuary-December
Net sales reached SEK 18.3 (17.2) millionThe operating result totaled SEK -10.2 (-13.7) million.Earnings... ► Artikel lesen | |
| 11.12.25 | Enzymatica AB: Enzymatica appoints Acting CFO during transition period | 263 | GlobeNewswire (Europe) | Enzymatica today announces the appointment of Kristina Rylander as Acting CFO during a transition period in the spring of 2026. She will assume the role on 1 March 2026, following the departure of the... ► Artikel lesen | |
| 20.11.25 | Enzymatica AB: Enzymatica enters partnership with the UK Sports Institute to support athlete health and performance | 433 | GlobeNewswire (Europe) | ColdZyme, the mouth spray developed by Enzymatica AB, has entered into a new partnership with the UK Sports Institute (UKSI) to support the institute's work in promoting athlete health and wellbeing.
The... ► Artikel lesen | |
| 30.10.25 | Enzymatica AB: Quarterly report Q3/2025: Strong development in Sweden and continued focus on international expansion | 421 | PR Newswire | LUND, Sweden, Oct. 30, 2025 /PRNewswire/ --
Third quarter
January-September
... ► Artikel lesen | |
| 13.10.25 | Enzymatica AB: Enzymatica appoints Holger Lembrér as new CFO | 442 | GlobeNewswire (Europe) | Enzymatica AB (publ) has appointed Holger Lembrér as new Chief Financial Officer (CFO). He will assume the position no later than April 2026 and will be part of the company's executive management team.
Holger... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 44,940 | -1,01 % | 90 Milliarden US-Dollar bis 2030: Wie Bayer, Mesoblast und NurExone regenerative Medizin unterschiedlich entwickeln | ||
| NOVO NORDISK | 33,210 | -0,48 % | Novo Nordisk gerät trotz GLP-1 unter Druck - warum Eli Lilly und Co. schon Milliarden in neue Plattformen investieren | ||
| PFIZER | 24,735 | +0,18 % | Litfulo and tilrekimig data bolster Pfizer's immunology plans | ||
| GILEAD SCIENCES | 128,68 | +0,09 % | Assembly Biosciences: Herpes-Countdown mit Gilead | ||
| SANOFI | 71,08 | -0,03 % | Laufende Fusionskontrollverfahren: Sanofi, Paris/FR; Erwerb eines Minderheitsanteils an der Cheplapharm SE (Gemeinschaftsunternehmen mit der Braun Invest Holding GmbH, Greifswald) | Datum der Anmeldung:24.09.2026Aktenzeichen:B3-102/26Unternehmen:Sanofi, Paris/FR; Erwerb eines Minderheitsanteils an der Cheplapharm SE (Gemeinschaftsunternehmen mit der Braun Invest Holding GmbH, Greifswald)Produktmärkte:Arzneimittel... ► Artikel lesen | |
| GSK | 20,870 | -1,04 % | JEFFERIES stuft GSK auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für GSK mit einem Kursziel von 2500 Pence auf "Buy" belassen. B7H3-Antikörper seien eine der am meisten unterschätzten Chancen... ► Artikel lesen | |
| ABBVIE | 231,00 | -0,35 % | AbbVie To Present New Dermatology Data At 2026 EADV Congress | WASHINGTON (dpa-AFX) - AbbVie (ABBV) said it will present new clinical and real-world data across its dermatology portfolio at the 2026 European Academy of Dermatology and Venereology (EADV)... ► Artikel lesen | |
| ASTRAZENECA | 139,30 | 0,00 % | Summit to Pair with AstraZeneca, Daiichi Sankyo to Evaluate Ivonescimab as Combination Therapy | ||
| INNOCAN PHARMA | 1,265 | -0,78 % | Innocan Pharma Corporation: VALITIC Expands Retail Industry Visibility Through Shoptalk Fall 2026 in Nashville, USA | HERZLIYA, Israel and CALGARY, Alberta, Sept. 29, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (OTCQB: INNPF) ("Innocan" or the "Company"), through B.I. Sky Global Ltd., its consumer... ► Artikel lesen | |
| TAAT GLOBAL ALTERNATIVES | 0,136 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -2- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameCA83013Q8719 CORE... ► Artikel lesen | |
| VIATRIS | 15,400 | -1,52 % | Dividendenbekanntmachungen (21.08.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACCO BRANDS CORPORATION US00081T1088 0,075 USD 0,0642 EUR ALLISON TRANSMISSION HOLDINGS INC US01973R1014 0,29 USD 0,2483 EUR AMGEN... ► Artikel lesen | |
| SINOPHARM | 1,649 | 0,00 % | Harbour BioMed and Sinopharm Enter Strategic Collaboration to Establish Innovation R&D Consortium | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 27, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed... ► Artikel lesen | |
| HALEON | 3,883 | +0,08 % | Haleon plc - 6-K, Report of foreign issuer | ||
| LIGAND PHARMACEUTICALS | 268,00 | -0,74 % | Ligand (LGND)-AvenCell Deal: Most of the Funding Is Tied to Milestones | ||
| ACHIEVE LIFE SCIENCES | 6,350 | 0,00 % | Achieve Life Sciences ernennt Benjamin Halladay zum neuen Finanzvorstand |